SeaCrest Wealth Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,643
| Closed | -$212K | – | 584 |
|
|
2026
Q1 | $212K | Buy |
2,643
+112
| +4% | +$9.23K | 0.02% | 588 |
|
|
2025
Q4 | $215K | Buy |
+2,531
| New | +$208K | 0.02% | 576 |
|
|
2025
Q3 | – | Sell |
-2,731
| Closed | -$214K | – | 646 |
|
|
2025
Q2 | $214K | Sell |
2,731
-1,250
| -31% | -$93.2K | 0.02% | 559 |
|
|
2025
Q1 | $289K | Sell |
3,981
-150
| -4% | -$10.7K | 0.03% | 488 |
|
|
2024
Q4 | $306K | Sell |
4,131
-11
| -0.3% | -$770 | 0.03% | 485 |
|
|
2024
Q3 | $273K | Buy |
4,142
+11
| +0.3% | +$799 | 0.03% | 516 |
|
|
2024
Q2 | $382K | Sell |
4,131
-295
| -7% | -$26.1K | 0.04% | 389 |
|
|
2024
Q1 | $423K | Sell |
4,426
-681
| -13% | -$57.2K | 0.05% | 350 |
|
|
2023
Q4 | $372K | Sell |
5,107
-503
| -9% | -$35K | 0.05% | 386 |
|
|
2023
Q3 | $389K | Buy |
5,610
+114
| +2% | +$9.16K | 0.05% | 370 |
|
|
2023
Q2 | $518K | Sell |
5,496
-84
| -2% | -$7.3K | 0.07% | 310 |
|
|
2023
Q1 | $462K | Buy |
5,580
+406
| +8% | +$31.9K | 0.06% | 341 |
|
|
2022
Q4 | $386K | Sell |
5,174
-2,250
| -30% | -$173K | 0.06% | 388 |
|
|
2022
Q3 | $613K | Buy |
7,424
+53
| +0.7% | +$5.1K | 0.09% | 241 |
|
|
2022
Q2 | $701K | Buy |
7,371
+51
| +0.7% | +$5.28K | 0.09% | 236 |
|
|
2022
Q1 | $862K | Sell |
7,320
-1,339
| -15% | -$150K | 0.1% | 212 |
|
|
2021
Q4 | $1.12M | Sell |
8,659
-127
| -1% | -$14.8K | 0.12% | 167 |
|
|
2021
Q3 | $995K | Buy |
8,786
+154
| +2% | +$17.6K | 0.12% | 184 |
|
|
2021
Q2 | $894K | Buy |
8,632
+120
| +1% | +$11.3K | 0.11% | 209 |
|
|
2021
Q1 | $712K | Buy |
8,512
+51
| +0.6% | +$4.31K | 0.09% | 231 |
|
|
2020
Q4 | $772K | Buy |
8,461
+1,200
| +17% | +$99.5K | 0.11% | 209 |
|
|
2020
Q3 | $580K | Sell |
7,261
-208
| -3% | -$16.2K | 0.09% | 226 |
|
|
2020
Q2 | $516K | Buy |
7,469
+344
| +5% | +$24.4K | 0.09% | 239 |
|
|
2020
Q1 | $448K | Sell |
7,125
-6
| -0.1% | -$433 | 0.1% | 226 |
|
|
2019
Q4 | $555K | Sell |
7,131
-45
| -0.6% | -$3.51K | 0.09% | 252 |
|
|
2019
Q3 | $526K | Buy |
7,176
+30
| +0.4% | +$2.11K | 0.1% | 247 |
|
|
2019
Q2 | $440K | Buy |
7,146
+24
| +0.3% | +$1.45K | 0.09% | 268 |
|
|
2019
Q1 | $454K | Buy |
7,122
+30
| +0.4% | +$1.71K | 0.08% | 252 |
|
|
2018
Q4 | $362K | Sell |
7,092
-2,508
| -26% | -$127K | 0.07% | 278 |
|
|
2018
Q3 | $557K | Sell |
9,600
-225
| -2% | -$11K | 0.09% | 233 |
|
|
2018
Q2 | $477K | Sell |
9,825
-696
| -7% | -$32.5K | 0.09% | 250 |
|
|
2018
Q1 | $489K | Sell |
10,521
-483
| -4% | -$21K | 0.09% | 243 |
|
|
2017
Q4 | $413K | Buy |
+11,004
| New | +$404K | 0.08% | 288 |
|
Other funds holding EW
SeaCrest Wealth Management's EW Position: Q2 2026 in Review
SeaCrest Wealth Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 2,643 shares — an estimated $212K sold.
SeaCrest Wealth Management first reported a position in EW in Q4 2017 and held it in 33 quarters. The position peaked at $1.12M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- SeaCrest Wealth Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
- SeaCrest Wealth Management sold 2,643 Edwards Lifesciences shares in Q2 2026, an estimated $212K.
- SeaCrest Wealth Management first reported a position in Edwards Lifesciences in Q4 2017 and held it in 33 quarters.
- SeaCrest Wealth Management's Edwards Lifesciences position peaked at $1.12M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.